Abstract: The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble Fc?R; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble Fc?R for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient.

Abstract: The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble Fc?R; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble Fc?R for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient.

Abstract: The invention relates to the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis.

Abstract: The invention relates to the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis.

Abstract: The invention relates to a method for determining the activity of nucleic acid sequences and to the use of the nucleic acid sequences identified in this way for providing diagnostic and therapeutic agents.

Abstract: An expression enhancer has a DNA sequence which is capable of forming a t-RNA clover-leaf structure after transcription and hybridizes in that region of the DNA which, after transcription, forms the anticodon loop in the clover-leaf structure with an oligonucleotide with the sequence 5'-GACTTAGAAGGTCGTT-3' or its complementary sequence (5'-AACGACCTTCTAAGTC-3'). It can be used to increase the yield in the expression of a recombinant gene by transformation of suitable host cells with an expression vector containing the recombinant gene, whereby it is likewise introduced into the host cells in a form capable of expression and expressed.

Abstract: An oligonucleotide probe specific for Neisseria gonorrhoeae is selected from the oligonucleotides RS2* and RS3*, RS2** and RS3**. It can have further nucleotides at its 5' end and/or 3' end. This probe is suitable for the specific detection of nucleic acids of the pathogenic species N. gonorrhoeae by hybrid formation under hybridization conditions.

Abstract: The present invention provides a plasmid suitable for the expression of penicillin G amidase, wherein it carries an incomplete penicillin G amidase gene in which the first 78 bases of the translated region on the 5' end of the complete gene are missing. This incomplete penicillin G amidase gene can also be present incorporated in the form of two separate fragments which commence with bases 79 and 868, respectively, counting from the translated region on the 5' end of the gene and displaying a deletion of the coding bases 705 to 867.The present invention also provides a process for the production of these plasmids and is also concerned with the use thereof for obtaining penicillin G amidase.

Abstract: A stable mutant form of creatine amidohydrolase is disclosed. This enzyme is formed via expression of altered DNA, which may be in plasmid form. Also disclosed is a method for determining creatinine using the mutant form.

Abstract: The present invention provides a micro-organism of the species Escherichia coli or Pseudomonas putida, wherein it constitutively forms creatinamidinohydrolase.The present invention also provides a process for the production of such a micro-organism.